The firm is a venture capital firm founded by experienced biotechnology entrepreneurs and focused exclusively on novel therapeutics. The firm invests at the earliest stages of company development, from Seed through late preclinical programs, and typically supports portfolio companies through clinical proof-of-concept before pursuing strategic exit opportunities. The firm generally makes initial equity investments of approximately $3M–5M, with the capacity to invest up to $15M–20M per company over the life of an investment. Investments are primarily made through equity, although convertible structures may be used selectively. While the firm’s current portfolio has a strong European focus, it takes a globally opportunistic approach and is expanding its focus toward North American opportunities.
The firm invests exclusively in therapeutics and is both modality- and indication-agnostic. The firm prioritizes highly innovative drug candidates with differentiated mechanisms of action, compelling scientific rationale, and significant unmet medical need. Rather than focusing on specific therapeutic areas, the firm emphasizes development stage, scientific quality, and commercial potential. In addition to participating in financing syndicates, the firm is also active in company creation and the formation of new biotechnology ventures.
From a company and management team perspective, the firm values experienced founders and leadership teams but does not impose strict requirements. The investment team works closely with portfolio companies on R&D strategy, capital allocation, financing, and corporate development, leveraging longstanding relationships with academic researchers, entrepreneurs, and biotechnology investors to help companies reach critical value-inflection milestones. The firm is open to acting as either a lead investor or co-investor depending on the opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment